N-(2,6-二甲基苯基)-N-甲基-乙酰胺 | 18835-47-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(2,6-二甲基苯基)-N-甲基-乙酰胺
• 英文名称: N,2',6'-trimethylacetanilide
• 英文别名: N-(2,6-dimethylphenyl)-N-methylacetamide；N-Methyl-N-acetyl-2,6-dimethyl-anilin；2--m-xylol；N-Acetyl-N-methyl-2,6-dimethyl-anilin；acetic acid-(2,6,N-trimethyl-anilide)；Essigsaeure-(2,6,N-trimethyl-anilid)；Essigsaeure-(methyl-vic.-m-xylidid)；N-Methyl-(acet-vic.-m-xylidid)；Acetamide, N-(2,6-dimethylphenyl)-N-methyl-
• CAS: 18835-47-7
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: FPQRDECXMGHKJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium 、 xylene 作用下， 生成 N-(2,6-二甲基苯基)-N-甲基-乙酰胺
  参考文献：
  名称：

  Friedlaender; Brand, Monatshefte fur Chemie, 1898, vol. 19, p. 641

  摘要：

  DOI：

文献信息

• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE L'HEPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2004103996A1

  公开（公告）日：2004-12-02

  Compounds of formula (I): wherein B, X, R3, L0, L1, L2, R2, R1 and RC are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

  公式（I）的化合物：其中B、X、R3、L0、L1、L2、R2、R1和RC的定义如本文所述。这些化合物可用作丙型肝炎病毒NS3蛋白酶的抑制剂，用于治疗丙型肝炎病毒感染。
• The copper-catalyzed aerobic oxidative amidation of tertiary amines
  作者：Hui-Cheng Cheng、Wen-Jun Hou、Zeng-Wen Li、Ming-Yu Liu、Bing-Tao Guan

  DOI：10.1039/c5cc07454a

  日期：——

  A general and efficient method for the tertiary amide synthesis has been developed via copper-catalyzed aerobic oxidative amidation of tertiary amines. Due to the use of O2 oxidant, various functional...

  通过铜催化的叔胺的好氧氧化酰胺化反应，已经开发出一种通用而有效的叔酰胺合成方法。由于使用了O2氧化剂，各种功能...
• Facile Synthesis of Substituted N-Monoalkylaromatic Amines Under PTC Conditions
  作者：U. R. Kalkote、A. R. Choudhary、A. A. Natu、R. J. Lahoti、N. R. Ayyangar

  DOI：10.1080/00397919108021779

  日期：1991.9

  Substituted aromatic amides were alkylated under PTC conditions. Compounds with ortho electron withdrawing substituents furnished exclusively monoalkyl amines. A plausible mechanism has been suggested.
• Pancreatic involvement in von Hippel–Lindau disease
  作者：Pascal R. Hammel、Valerie Vilgrain、Benoit Terris、Alfred Penfornis、Alain Sauvanet、Jean–Michel Correas、Dominique Chauveau、Axel Balian、Catherine Beigelman、Dermot O'Toole、Pierre Bernades、Philippe Ruszniewski、Stephane Richard

  DOI：10.1053/gast.2000.18143

  日期：2000.10

  Background & Aims: Pancreatic involvement in von Hippel-Lindau (VHL) disease, agenetic disorder with a dominant mode of inheritance affecting various organs, has rarely been studied, We assessed the prevalence, type of lesions, natural history, and impact of pancreatic involvement In patients with VHL, Methods: A total of 158 consecutive patients from 94 families with VHL disease were studied in a prospective French collaborative study, All patients underwent systematic screening for VHL lesions, including computerized tomography (CT) scanning of the pancreas reviewed by an experienced radiologist, Clinical data, investigations, and treatments performed were also reviewed, Results: Pancreatic involvement was observed in 122 patients (77.2%) and included true cysts (91.1%),serous cystadenomas (12.3%), neuroendocrine tumors (12.3%), or combined lesions (11.5%), The pancreas was the only organ affected in 7.6% of patients, Patients with pancreatic lesions had fewer pheochromocytomas than those without (14/122 vs, 16/36; P < 0.0001), and patients with neuroendocrine pancreatic tumors had venal involvement less often than those without (8/99 vs, 6/20; P = 0.013), None of the patients With neuroendocrine tumors had symptoms of hormonal hypersecretion. Pancreatic lesions evolved in half of patients but required specific treatment in only 10 (8.2%) when they were symptomatic or for the resection of large neuroendocrine tumors, Conclusions: Pancreatic involvement is seen in most patients with VHL disease. Although symptoms are rare, specific treatment of pancreatic lesions is required in selected patients, mainly those with neuroendocrine tumors.
• Friedlaender; Brand, Monatshefte fur Chemie, 1898, vol. 19, p. 641
  作者：Friedlaender、Brand

  DOI：——

  日期：——